Evidence map›Paper›PMID 40406109›Full record

ArticleFrontiers in immunology2025

Evaluation of humoral and cellular immune responses in healthcare workers with varying levels of SARS-CoV-2 exposure: effects of CoronaVac vaccination followed by heterologous booster.

Shayane Martins Rodrigues Gomes, Marcelo Ribeiro-Alves, Roberto Stefan de Almeida Ribeiro, Andréia Carolinne de Souza Brito, Vinicius da Cunha Lisboa, Samara Galdino de Azevedo, Jeane de Souza Nogueira, Leda Dos Reis Castilho, Luís Cristóvão Sobrino Pôrto, Silvia Amaral Gonçalves da Silva and 3 more

Abstract read
In one paragraph

Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Shayane Martins Rodrigues GomesDiscipline of Parasitology, Department of Microbiology, Immunology and Parasitology, Medical Science Faculty, Rio de Janeiro State University (UERJ), Rio de Janeiro, Brazil.
Marcelo Ribeiro-AlvesLaboratory of Clinical Research on ISTs/AIDS, National Institute of Infectology Evandro Chagas, Oswaldo Cruz Foundation (FIOCRUZ), Rio de Janeiro, Brazil.
Roberto Stefan de Almeida RibeiroLaboratory of Immunopathology (LIP), Discipline of General Pathology, Medical Science Faculty, UERJ, Rio de Janeiro, Brazil.
Andréia Carolinne de Souza BritoDiscipline of Parasitology, Department of Microbiology, Immunology and Parasitology, Medical Science Faculty, Rio de Janeiro State University (UERJ), Rio de Janeiro, Brazil.
Vinicius da Cunha LisboaLaboratory of Immunopathology (LIP), Discipline of General Pathology, Medical Science Faculty, UERJ, Rio de Janeiro, Brazil.
Samara Galdino de AzevedoLaboratory of Immunopathology (LIP), Discipline of General Pathology, Medical Science Faculty, UERJ, Rio de Janeiro, Brazil.
Jeane de Souza NogueiraLaboratory of Histocompatibility and Cryopreservation, Tissue Repair and Histocompatibility Technologic Core, Rio de Janeiro State University, Rio de Janeiro, Brazil.
Leda Dos Reis CastilhoCell Culture Engineering Lab, Chemical Engineering Program, Coordination of Graduate Engineering Programs, Federal University of Rio de Janeiro (UFRJ), Rio de Janeiro, Brazil.
Luís Cristóvão Sobrino PôrtoLaboratory of Histocompatibility and Cryopreservation, Tissue Repair and Histocompatibility Technologic Core, Rio de Janeiro State University, Rio de Janeiro, Brazil.
Silvia Amaral Gonçalves da SilvaDiscipline of Parasitology, Department of Microbiology, Immunology and Parasitology, Medical Science Faculty, Rio de Janeiro State University (UERJ), Rio de Janeiro, Brazil.
Patrícia Maria Lourenço DutraDiscipline of Parasitology, Department of Microbiology, Immunology and Parasitology, Medical Science Faculty, Rio de Janeiro State University (UERJ), Rio de Janeiro, Brazil.
Wânia Ferraz Pereira ManfroDiscipline of Microbiology and Immunology, Department of Microbiology, Immunology and Parasitology, Medical Science Faculty, UERJ, Rio de Janeiro, Brazil.
Luciana Silva RodriguesLaboratory of Immunopathology (LIP), Discipline of General Pathology, Medical Science Faculty, UERJ, Rio de Janeiro, Brazil.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The COVID-19 pandemic demanded diverse vaccination strategies, and there is significant interest in their effectiveness in generating a robust immune response. In Brazil, the use of CoronaVac was crucial in reducing mortality; however, heterologous booster doses were necessary to enhance memory immune response. This study aimed to evaluate the humoral and cellular immunity in healthcare workers who were vaccinated with a complete regimen of CoronaVac and subsequently received heterologous booster doses over nearly one year. Methods: A longitudinal study recruited healthcare professionals with varying levels of exposure to SARS-CoV-2 from the Health Complex of the Rio de Janeiro State University (UERJ), Rio de Janeiro, Brazil. Blood samples were collected at five time points, including baseline and after vaccination with CoronaVac and heterologous booster doses (ChAdOx1 nCov-19 or BNT162b2). The Th1/Th2/Th17 cytokine production was measured by Flow Cytometry, using whole blood samples stimulated or not with the SARS-CoV-2 Spike protein. In parallel, serum levels of IgG antibodies against Spike (anti-S) and Nucleocapsid (anti-N) proteins were assessed using an immunoassay. Adjustments were made for confounding factors, including age, sex, level of SARS-CoV-2 exposure, and COVID-19 infection status. Results: Our results demonstrate that CoronaVac induced high anti-S IgG levels at all evaluated time points (P<0.01). Cytokine analysis revealed a sustained production of antigen-specific Th1 cytokines, including IL-2 (P<0.01) and IFN-γ (P<0.05) regardless of level of SARS-CoV-2 exposure or previous COVID-19 infection at any point during the study. Additionally, we identified six moderate to strong positive correlations (P<0.0001): IL-10 and IFN-γ (ρ=0.77), IL-6 and TNF (ρ=0.77), IL-2 and IFN-γ (ρ=0.71), IL-6 and IL-10 (ρ=0.66), anti-N IgG and anti-S IgG (ρ=0.62), and IL-2 and anti-S IgG (ρ=0.62). Conclusion: The CoronaVac elicited an antigen-specific cellular immune response, characterized by enhancing the production of key cytokines such as IFN-γ and IL-2, with high levels of anti-S IgG. Furthermore, the administration of heterologous boosters significantly enhanced these immune responses, demonstrating induced-specific immunological response. These findings underscore the importance of primary vaccination and boosters in inducing immune protection against COVID-19, potentially informing future vaccination policies and approaches.

Indexed as

COVID-19COVID-19 VaccinesHealth PersonnelImmunity, CellularImmunity, HumoralSARS-CoV-2AdultAntibodies, ViralBNT162 VaccineBrazilChAdOx1 nCoV-19CytokinesFemaleHumansImmunization, SecondaryImmunoglobulin GAntibodies, ViralBNT162 VaccineChAdOx1 nCoV-19COVID-19 VaccinesCytokinesImmunoglobulin Gsinovac COVID-19 vaccineSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2Vaccines, InactivatedCoronaVaccytokineshealthcare workersheterologous boosterhumoral immunity

Identifiers

PMID40406109
PMCPMC12095306

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.